Mechanisms of cancer pain

Molecular Interventions

Volumn 10, Issue 3, 2010, Pages 164-178

  Schmidt, Brian L ^a   Hamamoto, Darryl T ^b   Simone, Donald A ^b   Wilcox, George L ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ATRASENTAN; BRADYKININ; BRADYKININ B1 RECEPTOR ANTAGONIST; CAPSAZEPINE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR AGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ETANERCEPT; MORPHINE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NALOXONE; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; PLACEBO; PROTEINASE ACTIVATED RECEPTOR 2; RIMONABANT; RUTHENIUM RED; TUMOR NECROSIS FACTOR ALPHA; VANILLOID RECEPTOR 1;

ALLODYNIA; ANALGESIA; ANTINOCICEPTION; BONE CANCER; BREAST CANCER; CANCER CELL; CANCER PAIN; CANCER PATIENT; CLINICAL FEATURE; CLINICAL TRIAL; COMPETITIVE INHIBITION; DRUG DOSE ESCALATION; HUMAN; HYPERALGESIA; IMMUNOCOMPETENT CELL; METASTASIS; MICROENVIRONMENT; MOUTH CARCINOMA; NEUROCHEMISTRY; NOCICEPTION; NOCICEPTIVE RECEPTOR; NONHUMAN; PERIPHERAL NEUROPATHY; PROSTATE CANCER; RECEPTOR DOWN REGULATION; REVIEW; SENSITIZATION; SENSORY NERVE; SENSORY NERVE CELL; SOFT TISSUE CANCER; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; ANIMAL; BIOLOGICAL MODEL; NEOPLASM; PAIN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NOCICEPTORS; PAIN;

EID: 77953501129     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.10.3.7     Document Type: Review

References (166)

1. List MA, Stracks J, Colangelo L et al. (2000) How Do head and neck cancer patients prioritize treatment outcomes before initiating treatment? J Clin Oncol 18:877-84. (Pubitemid 30106620)
2. Hamamoto DT, Khasabov SG, Cain DM, and Simone DA (2008) Tumor-evoked sensitization of C nociceptors: a role for endothelin. J Neurophysiol 100:2300-11.
3. Sabino MA, Luger NM, Mach DB, Rogers SD, Schwei MJ, and Mantyh PW (2003) Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system. Int J Cancer 104:550-8.
4. Sabino MA, Ghilardi JR, Jongen JL et al. (2002) Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 62:7343-9.
5. Lan LS, Ping YJ, Na WL, Miao J, Cheng QQ, Ni MZ, Lei L, Fang LC, Guang RC, Jin Z, and Wei L (2010) Down-regulation of Toll-like receptor 4 gene expression by short interfering RNA attenuates bone cancer pain in a rat model. Mol Pain 6:2.
6. Gokin AP, Fareed MU, Pan HL, Hans G, Strichartz GR, and Davar G (2001) Local injection of endothelin-1 produces pain-like behavior and excitation of nociceptors in rats. J Neurosci 21:5358-66.
7. Hans G, Deseure K, Robert D, and De Hert S (2007) Neurosensory changes in a human model of endothelin-1 induced pain: a behavioral study. Neurosci Lett 418:117-21.
8. Khodorova A, Navarro B, Jouaville LS et al. Murphy JE, Rice FL, Mazurkiewicz JE, Long-Woodward D, Stoffel M, Strichartz GR, Yukhananov R, and Davar G (2003) Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury Nat Med 9:1055-61.
9. Davar G Endothelin-1 and metastatic cancer pain. Pain Med 2:24-7 (2001)
10. Pickering V, Jay Gupta R, Quang P, Jordan RC, and Schmidt BL (2007) Effect of peripheral endothelin-1 concentration on carcinoma-induced pain in mice. Eur J Pain 12:293-300.
11. Pomonis JD, Rogers SD, Peters CM, Ghilardi JR, and Mantyh PW (2001) Expression and localization of endothelin receptors: implications for the involvement of peripheral glia in nociception. J Neurosci 21:999-1006.
12. Peters CM, Lindsay TH, Pomonis JD, Luger NM, Ghilardi JR, Sevcik MA, and Mantyh PW (2004) Endothelin and the tumorigenic component of bone cancer pain. Neuroscience 126:1043-52.
13. Wintzen M, Yaar M, Burbach JP, and Gilchrest BA (1996) Proopiomelanocortin gene product regulation in keratinocytes. J Invest Dermatol 106:673-8.
14. Wintzen M, Zanello SB, Holick MF, Wiegant VM, Burbach JP, and Vermeer BJ (2000) Condition-dependent presence of beta-lipotropin-like peptide in human keratinocytes. Peptides 21:691-7.
15. Zanello SB, Jackson DM, and Holick MF (1999) An immunocytochemical approach to the study of beta-endorphin production in human keratinocytes using confocal microscopy. Ann N Y Acad Sci 885:85-99.
16. Boyce BF, Yoneda T, and Guise TA (1999) Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 6:333-47.
17. Guise TA (2000) Molecular mechanisms of osteolytic bone metastases. Cancer 88:2892-8.
18. Chiao JW, Moonga BS, Yang YM, Kancherla R, Mittelman A, Wu-Wong JR, and Ahmed T (2000) Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 83:360-5.
19. Nelson J, Bagnato A, Battistini B, and Nisen P (2003) The endothelin axis: emerging role in cancer. Nat Rev Cancer 3:110-6.
20. Rauh A, Windischhofer W, Kovacevic A et al. (2008) Endothelin (ET)-1 and ET-3 promote expression of c-fos and c-jun in human choriocarcinoma via ET(B) receptor-mediated G(i)- and G(q)-pathways and MAP kinase activation. Br J Pharmacol 154:13-24.
21. Cain DM, Wacnik PW, Turner M, Wendelschafer-Crabb G, Kennedy WR, Wilcox GL, and Simone DA (2001) Functional interactions between tumor and peripheral nerve: changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain. J Neurosci 21:9367-76.
22. Wacnik PW, Eikmeier LJ, Ruggles TR, Ramnaraine ML, Walcheck BK, Beitz AJ, and Wilcox GL (2001) Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J Neurosci 21:9355-66.
23. Gokin AP, Pan H, Sinnott C, Strichartz G, and Davar G (2000) Selective, endothelin-A receptor-dependent, excitation of nociceptive sensory fibers by endothelin-1 applied to the rat plantar hindpaw. SfN Abstracts 6344:1694.
24. Khodorova A, Fareed MU, Gokin A, Strichartz GR, and Davar G (2002) Local injection of a selective endothelin-B receptor agonist inhibits endothelin-1-induced pain-like behavior and excitation of nociceptors in a naloxone-sensitive manner. J Neurosci 22:7788-96.
25. Quang PN and Schmidt BL (2010) Endothelin-A receptor antagonism attenuates carcinoma-induced pain through opioids in mice. J Pain (Epub ahead of print PMID: 20071245).
26. Yuyama H, Koakutsu A, Fujiyasu N et al. (2004) Inhibitory Effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. J Cardiovasc Pharmacol 44:S479-82.
27. Schmidt BL, Pickering V, Liu S, Quang P, Dolan J, Connelly ST, and Jordan RC (2007) Peripheral endothelin A receptor antagonism attenuates carcinoma-induced pain. Eur J Pain 11:406-14.
28. Connelly ST and Schmidt BL (2004) Evaluation of pain in patients with oral squamous cell carcinoma. J Pain 5:505-10.
29. Kolokythas A, Connelly ST, and Schmidt BL (2007) Validation of the university of california san francisco oral cancer pain questionnaire. J Pain 8:950-3.
30. Carducci MA, Padley RJ, Breul J et al. (2003) Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21:679-89.
31. Carducci MA, Nelson JB, Bowling MK et al. (2002) Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 20:2171-80.
32. Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ, Qian J, Steinberg J, and Carducci M (2008) Phase 3-randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 113:2478-87.
33. Wulfing P, Diallo R, Kersting C, Wulfing C, Poremba C, Rody A, Greb RR, Bocker W, and Kiesel L (2003) Expression of endothelin-1:endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clin Cancer Res 9:4125-31. (Pubitemid 37204029)
34. Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, and Balkwill FR (2004) A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res 64:2461-8.
35. Jeronimo C, Henrique R, Campos PF, Oliveira J, Caballero OL, Lopes C, and Sidransky D (2003) Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. J Clin Pathol 56:52-5.
36. Pao MM, Tsutsumi M, Liang G, Uzvolgyi E, Gonzales FA, and Jones PA (2001) The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. Hum Mol Genet 10:903-10.
37. Lahav R, Heffner G, and Patterson PH (1999) An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci U S A 96:11496-500.
38. Bagnato A, Rosano L, Spinella F, Di Castro V, Tecce R, and Natali PG (2004) Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res 64:1436-43.
39. Bagnato A and Rosano L (2008) The endothelin axis in cancer. Int J Biochem Cell Biol 40:1443-51.
40. Piovezan AP, D'Orleans-Juste P, Tonussi CR, and Rae GA (1998) Effects of endothelin-1 on capsaicin-induced nociception in mice. Eur J Pharmacol 351:15-22.
41. Piovezan AP, D'Orleans-Juste P, Souza GE, and Rae GA (2000) Endothelin-1-induced ET(A) receptor-mediated nociception, hyperalgesia and oedema in the mouse hind-paw: modulation by simultaneous ET(B) receptor activation. Br J Pharmacol 129:961-8.
42. Piovezan AP, D'Orleans-Juste P, Frighetto M, Souza GE, Henriques MG, and Rae GA (2004) Endothelins contribute towards nociception induced by antigen in ovalbumin-sensitised mice. Br J Pharmacol 141:755-63.
43. Quang PN and Schmidt BL (2010) Peripheral endothelin B receptor agonist-induced antinociception involves endogenous opioids in mice. Pain 149:254-62.
44. Haberberger RV and Bodenbenner M (2000) Immunohistochemical localization of muscarinic receptors (M2) in the rat skin. Cell Tissue Res 300:389-96.
45. Lewin GR and Mendell LM (1993) Nerve growth factor and nociception. Trends Neurosci 16:353-9.
46. Nagahama M, Funasaka Y, Fernandez-Frez ML, Ohashi A, Chakraborty AK, Ueda M, and Ichihashi M (1998) Immunoreactivity of alpha-melanocyte-stimulating hormone, adrenocorticotrophic hormone and beta-endorphin in cutaneous malignant melanoma and benign melanocytic naevi. Br J Dermatol 138:981-5.
47. Melzig MF, Nylander I, Vlaskovska M, and Terenius L (1995) Beta-endorphin stimulates proliferation of small cell lung carcinoma cells in vitro via nonopioid binding sites. Exp Cell Res 219:471-6.
48. Omar RA and el Tabbakh GH (1987) Immunoreactive beta-endorphin in ovarian sex cord-stromal tumors. Arch Pathol Lab Med 111:436-9.
49. Schauer E, Trautinger F, Kock A, Schwarz A, Bhardwaj R, Simon M, Ansel JC, Schwarz T, and Luger TA (1994) Proopiomelanocortin-derived peptides are synthesized and released by human keratinocytes. J Clin Invest 93:2258-62.
50. Machelska H and Stein C (2000) Pain control by immune-derived opioids. Clin Exp Pharmacol Physiol 27:533-6.
51. Rittner HL, Brack A, Machelska H, Mousa SA, Bauer M, Schafer M, and Stein C (2001) Opioid peptide-expressing leukocytes: identification, recruitment, and simultaneously increasing inhibition of inflammatory pain. Anesthesiology 95:500-8.
52. Harada N, Himeno A, Shigematsu K, Sumikawa K, and Niwa M (2002) Endothelin-1 binding to endothelin receptors in the rat anterior pituitary gland: possible formation of an ETA-ETB receptor heterodimer. Cell Mol Neurobiol 22:207-26.
53. Bhalla S, Ciaccio N, Wang ZJ, and Gulati A (2006) Involvement of endothelin in morphine tolerance in neuroblastoma (SH-SY5Y) cells. Exp Biol Med (Maywood) 231:1152-6.
54. Bhalla S, Matwyshyn G, and Gulati A (2005) Morphine tolerance does not develop in mice treated with endothelin-A receptor antagonists. Brain Res 1064:126-35.
55. Puppala BL, Matwyshyn G, Bhalla S, and Gulati A (2004) Role of endothelin in neonatal morphine tolerance. J Cardiovasc Pharmacol 44:S383-S385.
56. Bhalla S, Matwyshyn G, and Gulati A (2003) Endothelin receptor antagonists restore morphine analgesia in morphine tolerant rats. Peptides 24:553-61.
57. Ghilardi JR, Rohrich H, Lindsay TH et al. (2005) Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci 25:3126-31.
58. Shinoda M, Ogino A, Ozaki N, Urano H, Hironaka K, Yasui M, and Sugiura Y (2008) Involvement of TRPV1 in nociceptive behavior in a rat model of cancer pain. J Pain 9:687-99.
59. Nagae M, Hiraga T, and Yoneda T (2007) Acidic microenvironment created by osteoclasts causes bone pain associated with tumor colonization. J Bone Miner Metab 25:99-104.
60. Soreide K, Janssen EA, Korner H, and Baak JP (2006) Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis. J Pathol 209:147-56.
61. DeClerck YA, Mercurio AM, Stack MS et al. (2004) Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol 164:1131-9.
62. Ohta T, Amaya K, Yi S et al. (2003) Angiotensin converting enzyme-independent, local angiotensin II-generation in human pancreatic ductal cancer tissues. Int J Oncol 23:593-8.
63. Nyberg P, Ylipalosaari M, Sorsa T, and Salo T (2006) Trypsins and their role in carcinoma growth. Exp Cell Res 312:1219-28.
64. Ossovskaya VS and Bunnett NW (2004) Protease-activated receptors: contribution to physiology and disease. Physiol Rev 84:579-621.
65. Hoogerwerf WA, Zou L, Shenoy M et al. (2001) The proteinase-activated receptor 2 is involved in nociception. J Neurosci 21:9036-42.
66. Alier K A, Endicott JA, Stemkowski PL et al. (2008) Intrathecal administration of proteinase-activated receptor-2 agonists produces hyperalgesia by exciting the cell bodies of primary sensory neurons. J Pharmacol Exp Ther 324:224-33.
67. Steinhoff M, Vergnolle N, Young SH et al. (2000) Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 6:151-8.
68. Amadesi S, Cottrell GS, Divino L et al. (2006) Protease-activated receptor 2 sensitizes TRPV1 by protein kinase Cepsilon- and A-dependent mechanisms in rats and mice. J Physiol 575:555-71.
69. Grant AD, Cottrell GS, Amadesi S et al. (2007) Protease-activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice. J Physiol 578:715-33.
70. Lam DK and Schmidt BL (2010) Serine proteases and protease-activated receptor 2-dependent allodynia: a novel cancer pain pathway. Pain 149:263-72.
71. Koshikawa N, Hasegawa S, Nagashima Y et al. (1998) Expression of trypsin by epithelial cells of various tissues, leukocytes, and neurons in human and mouse. Am J Pathol 153:937-44. (Pubitemid 28419046)
72. Koshikawa N, Nagashima Y, Miyagi Y, Mizushima H, Yanoma S, Yasumitsu H, and Miyazaki K (1997) Expression of trypsin in vascular endothelial cells. FEBS Lett 409:442-8.
73. Ichikawa Y, Koshikawa N, Hasegawa S et al. (2000) Marked increase of trypsin(ogen) in serum of linitis plastica (gastric cancer, borrmann 4) patients. Clin Cancer Res 6:1385-8.
74. Barki-Harrington L and Daaka Y (2001) Bradykinin induced mitogenesis of androgen independent prostate cancer cells. J Urol 165:2121-5.
75. Sevcik MA, Ghilardi JR, Halvorson KG, Lindsay TH, Kubota K, and Mantyh PW (2005) Analgesic efficacy of bradykinin B1 antagonists in a murine bone cancer pain model. J Pain 6:771-5.
76. Fujita M, Andoh T, Ohashi K, Akira A, Saiki I, and Kuraishi Y (2009) Roles of kinin B(1) and B(2) receptors in skin cancer pain produced by orthotopic melanoma inoculation in mice. Eur J Pain (Epub ahead of print PMID: 19932979).
77. Andoh T, Akira A, Saiki I, and Kuraishi Y (2010) Bradykinin increases the secretion and expression of endothelin-1 through kinin B2 receptors in melanoma cells. Peptides 31:238-41.
78. Friedman WJ and Greene LA (1999) Neurotrophin signaling via Trks and p75. Exp Cell Res 253:131-42.
79. Descamps S, Lebourhis X, Delehedde M, Boilly B, and Hondermarck H (1998) Nerve growth factor is mitogenic for cancerous but not normal human breast epithelial cells. J Biol Chem 273:16659-62.
80. Descamps S, Pawlowski V, Revillion F, Hornez L, Hebbar M, Boilly B, Hondermarck H, and Peyrat JP (2001) Expression of nerve growth factor receptors and their prognostic value in human breast cancer. Cancer Res 61:4337-40.
81. Descamps S, Toillon RA, Adriaenssens E et al. (2001) Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J Biol Chem 276:17864-70.
82. Geldof AA, De Kleijn MA, Rao BR, and Newling DW (1997) Nerve growth factor stimulates in vitro invasive capacity of DU145 human prostatic cancer cells. J Cancer Res Clin Oncol 123:107-12.
83. Geldof AA, Van Haarst EP, and Newling DW (1998) Neurotrophic factors in prostate and prostatic cancer. Prostate Cancer Prostatic Dis 1:236-241.
84. Zhu Z, Friess H, diMola FF, Zimmermann A, Graber HU, Korc M, and Buchler MW (1999) Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol 17:2419-28.
85. Davidson B, Lazarovici P, Ezersky A et al. (2001) Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients. Clin Cancer Res 7:3457-64.
86. Davidson B, Reich R, Lazarovici P, Ann Florenes V, Nielsen S, and Nesland JM (2004) Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat 83:119-28.
87. Davidson B, Reich R, Lazarovici P et al. (2004) Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. Lung Cancer 44:159-65.
88. Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B, Trope CG, and Florenes VA (2003) Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res 9:2248-59.
89. Dolle L, Adriaenssens E, El Yazidi-Belkoura I, Le Bourhis X, Nurcombe V, and Hondermarck H (2004) Nerve growth factor receptors and signaling in breast cancer. Curr Cancer Drug Targets 4:463-70.
90. Dolle L, El Yazidi-Belkoura I, Adriaenssens E, Nurcombe V, and Hondermarck H (2003) Nerve growth factor overexpression and autocrine loop in breast cancer cells. Oncogene 22:5592-601.
91. Sakamoto Y, Kitajima Y, Edakuni G, Hamamoto T, and Miyazaki K (2001) Combined evaluation of NGF and p75NGFR expression is a biomarker for predicting prognosis in human invasive ductal breast carcinoma. Oncol Rep 8:973-80.
92. Sortino MA, Condorelli F, Vancheri C, Chiarenza A, Bernardini R, Consoli U, and Canonico PL (2000) Mitogenic effect of nerve growth factor (NGF) in LNCaP prostate adenocarcinoma cells: role of the high- and low-affinity NGF receptors. Mol Endocrinol 14:124-36.
93. Tagliabue E, Castiglioni F, Ghirelli C, Modugno M, Asnaghi L, Somenzi G, Melani C, and Menard S (2000) Nerve growth factor cooperates with p185(HER2) in activating growth of human breast carcinoma cells. J Biol Chem 275:5388-94.
94. Kolokythas A, Cox DP, Dekker N, and Schmidt BL (2010) Nerve growth factor (NGF) and tyrosine kinase A (Trk A) receptor in oral squamous cell carcinoma: is there an association with perineural invasion? J. Oral Maxillofacial Surg. (in press).
95. Lewin GR, Ritter AM, and Mendell LM (1993) Nerve growth factor-induced hyperalgesia in the neonatal and adult rat. J Neurosci 13:2136-48.
96. Amann R, Schuligoi R, Herzeg G, and Donnerer J (1996) Intraplantar injection of nerve growth factor into the rat hind paw: local edema and effects on thermal nociceptive threshold. Pain 64:323-9.
97. Davis BM, Lewin GR, Mendell LM, Jones ME, and Albers KM (1993) Altered expression of nerve growth factor in the skin of transgenic mice leads to changes in response to mechanical stimuli. Neuroscience 56:789-92.
98. Raychaudhuri SP, Jiang WY, and Farber EM (1998) Psoriatic keratinocytes express high levels of nerve growth factor. Acta Derm Venereol 78:84-6.
99. di Mola FF, Friess H, Zhu Z W, Koliopanos A, Bley T, Di Sebastiano P, Innocenti P, Zimmermann A, and Buchler MW (2000) Nerve growth factor and Trk high affinity receptor (TrkA) gene expression in inflammatory bowel disease. Gut 46:670-9.
100. Aloe L, Tuveri M A, Carcassi U, and Levi-Montalcini R (1992) Nerve growth factor in the synovial fluid of patients with chronic arthritis. Arthritis Rheum 35:351-5.
101. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, and Leon A (1996) Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci 19:514-20.
102. McMahon SB (1996) NGF as a mediator of inflammatory pain. Philos Trans R Soc Lond B Biol Sci 351:431-40.
103. Rueff A and Mendell LM (1996) Nerve growth factor NT-5 induce increased thermal sensitivity of cutaneous nociceptors in vitro. J Neurophysiol 76:3593-6.
104. Weskamp G and Otten U (1987) An enzyme-linked immunoassay for nerve growth factor (NGF): a tool for studying regulatory mechanisms involved in NGF production in brain and in peripheral tissues. J Neurochem 48:1779-86.
105. Donnerer J, Schuligoi R, and Stein C (1992) Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: evidence for a regulatory function of nerve growth factor in vivo. Neuroscience 49:693-8.
106. Galeazza MT, Garry MG, Yost HJ, Strait KA, Hargreaves KM, and Seybold VS (1995) Plasticity in the synthesis and storage of substance P and calcitonin gene-related peptide in primary afferent neurons during peripheral inflammation. Neuroscience 66:443-58.
107. Garry MG and Hargreaves KM (1992) Enhanced release of immuno-reactive CGRP and substance P from spinal dorsal horn slices occurs during carrageenan inflammation. Brain Res 582:139-42.
108. Southall MD, Michael RL, and Vasko MR (1998) Intrathecal NSAIDS attenuate inflammation-induced neuropeptide release from rat spinal cord slices. Pain 78:39-48.
109. Ji RR, Samad TA, Jin S X, Schmoll R, and Woolf CJ (2002) p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 36:57-68.
110. Fjell J, Cummins TR, Davis BM, Albers KM, Fried K, Waxman SG, and Black JA (1999) Sodium channel expression in NGF-overexpressing transgenic mice. J Neurosci Res 57:39-47.
111. Gould HJ, 3rd Gould TN, England JD, Paul D, Liu ZP, and Levinson SR (2000) A possible role for nerve growth factor in the augmentation of sodium channels in models of chronic pain. Brain Res 854:19-29.
112. Petersen M, Segond von Banchet G, Heppelmann B, and Koltzenburg M (1998) Nerve growth factor regulates the expression of bradykinin binding sites on adult sensory neurons via the neurotrophin receptor p75. Neuroscience 83:161-8.
113. Ramer MS, Bradbury EJ, and McMahon SB (2001) Nerve growth factor induces P2X(3) expression in sensory neurons. J Neurochem 77:864-75.
114. Mamet J, Baron A, Lazdunski M, and Voilley N (2002) Proinflammatory mediators, stimulators of sensory neuron excitability via the expression of acid-sensing ion channels. J Neurosci 22:10662-70.
115. Wang L, Sun M, Jiang Y, Yang L, Lei D, Lu C, Zhao Y, Zhang P, Yang Y, and Li J (2006) Nerve growth factor and tyrosine kinase A in human salivary adenoid cystic carcinoma: expression patterns and effects on in vitro invasive behavior. J Oral Maxillofac Surg 64:636-41.
116. Ma J, Jiang Y, Jiang Y, Sun Y, and Zhao X (2008) Expression of nerve growth factor and tyrosine kinase receptor A and correlation with perineural invasion in pancreatic cancer. J Gastroenterol Hepatol 23:1852-9.
117. Halvorson KG, Kubota K, Sevcik MA et al. (2005) A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 65:9426-35.
118. Woolf CJ, Allchorne A, Safieh-Garabedian B, and Poole S (1997) Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol 121:417-24.
119. Wacnik PW, Eikmeier LJ, Simone DA, Wilcox GL, and Beitz AJ (2005) Nociceptive characteristics of tumor necrosis factor-alpha in naive and tumor-bearing mice. Neuroscience 132:479-91.
120. Constantin CE, Mair N, Sailer CA et al. (2008) Endogenous tumor necrosis factor alpha (TNFalpha) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model. J Neurosci 28:5072-81.
121. Noyes R, Jr, Brunk SF, Baram DA, and Canter A (1975) Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 15:139-43.
122. Fuentes JA, Ruiz-Gayo M, Manzanares J, Vela G, Reche I, and Corchero J (1999) Cannabinoids as potential new analgesics. Life Sci 65:675-85.
123. Gardell LR, Wang R, Burgess SE, Ossipov MH, Vanderah TW, Malan TP Jr, Lai J, and Porreca F (2002) Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci 22:6747-55.
124. Lichtman AH and Martin, BR (1991) Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther 258:517-23.
125. Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569-611.
126. Karst M, Salim K, Burstein S, Conrad I, Hoy L, and Schneider U (2003) Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. Jama 290:1757-62.
127. Cichewicz DL and Welch SP (2003) Modulation of oral morphine anti-nociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 305:812-7.
128. Cichewicz DL and McCarthy EA (2003) Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther 304:1010-5.
129. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-4.
130. Munro S, Thomas KL, and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-5.
131. Finn DP, Jhaveri MD, Beckett SR, Roe CH, Kendall DA, Marsden CA, and Chapman V (2003) Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology 45:594-604.
132. Freund TF, Katona I, and Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017-66.
133. Salio C, Cottone E, Conrath M, and Franzoni MF (2002) CB1 cannabinoid receptors in amphibian spinal cord: relationships with some nociception markers. J Chem Neuroanat 24:153-62.
134. Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, Porreca F, Buckley NE, Makriyannis A, and Malan TP Jr (2006) CB2 cannabinoid receptor mediation of antinociception. Pain 122:36-42.
135. Hohmann AG and Herkenham M (1999) Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 92:1171-5.
136. Agarwal N, Pacher P, Tegeder I et al. (2007) Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10:870-9.
137. Schatz AR, Lee M, Condie RB, Pulaski JT, and Kaminski NE (1997) Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 142:278-87.
138. Ibrahim MM, Porreca F, Lai J et al. (2005) CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 102:3093-8.
139. Kehl L , Hamamoto DT, Wacnik PW, Croft DL, Norsted BD, Wilcox GL, and Simone DA (2003) A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain 103:175-86.
140. Hamamoto DT, Giridharagopalan S, and Simone DA (2007) Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia. Eur J Pharmacol 558:73-87.
141. Guerrero AV, Quang P, Dekker N, Jordan RC, and Schmidt BL (2008) Peripheral cannabinoids attenuate carcinoma-induced nociception in mice. Neurosci Lett. 433:77-81.
142. Casanova ML, Blazquez C, Martinez-Palacio J et al. (2003) Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111:43-50.
143. Davar G, Hans G, Fareed MU, Sinnott C, and Strichartz G (1998) Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve. Neuroreport 9:2279-83.
144. Nelson JB and Carducci MA (2000) The role of endothelin-1 and endothelin receptor antagonists in prostate cancer. BJU Int 85:45-8.
145. Schwei MJ, Honore P, Rogers SD et al. (1999) Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 19:10886-97.
146. Clohisy DR, Ogilvie CM, and Ramnaraine ML (1995) Tumor osteolysis in osteopetrotic mice. J Orthop Res 13:892-7.
147. Clohisy DR, Ogilvie CM, Carpenter RJ, and Ramnaraine ML (1996) Localized, tumor-associated osteolysis involves the recruitment and activation of osteoclasts. J Orthop Res 14:2-6.
148. Wacnik PW, Wilcox GL, Clohisy DR, Ramnaraine ML, Eikmeier LJ, Beitz AJ 2000Animal models of cancer pain, in Pain Research and Clinical Management: Proceedings of the Ninth World Congress on Pain, -(HM Devor ed) IASP Press, Seattle p 615-637.
149. Abbadie C, Trafton J, Liu H, Mantyh PW, and Basbaum AI (1997) Inflammation increases the distribution of dorsal horn neurons that internalize the neurokinin-1 receptor in response to noxious and non-noxious stimulation. J Neurosci 17:8049-60.
150. Honore P, Menning PM, Rogers SD, Nichols ML, Basbaum AI, Besson JM, and Mantyh PW (1999) Spinal substance P receptor expression and internalization in acute, short-term, and long-term inflammatory pain states. J Neurosci 19:7670-8.
151. Hunt SP, Pini A, and Evan G (1987) Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature 328:632-4.
152. Doyle CA and Hunt SP (1999) Substance P receptor (neurokinin-1)- expressing neurons in lamina I of the spinal cord encode for the intensity of noxious stimulation: a c-Fos study in rat. Neuroscience 89:17-28.
153. Abbadie C, Taylor BK, Peterson MA, and Basbaum AI (1997) Differential contribution of the two phases of the formalin test to the pattern of c-fos expression in the rat spinal cord: studies with remifentanil and lidocaine. Pain 69:101-10.
154. Honore P, Rogers SD, Schwei MJ, Salak-Johnson JL, Luger NM, Sabino MC, Clohisy DR, and Mantyh PW (2000) Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 98:585-98.
155. Schweizerhof M, Stosser S, Kurejova M et al. (2009) Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat Med 15:802-7.
156. Khasabova IA, Khasabov SG, Harding-Rose C et al. (2008) A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J Neurosci 28:11141-52.
157. Simone DA, Nolano M, Johnson T, Wendelschafer-Crabb G, and Kennedy WR (1998) Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function. J Neurosci 18:8947-59.
158. Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, and Kennedy WR (1999) Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain 81:135-45.
159. Shimoyama M, Tanaka K, Hasue F, and Shimoyama N (2002) A mouse model of neuropathic cancer pain. Pain 99:167-74.
160. Vanderah TW, Laughlin T, Lashbrook JM et al. (1996) Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long-lasting allodynia in rats: blockade by MK-801 but not naloxone. Pain 68:275-81.
161. Kajander KC, Sahara Y, Iadarola MJ, and Bennett GJ (1990) Dynorphin increases in the dorsal spinal cord in rats with a painful peripheral neuropathy. Peptides 11:719-28.
162. Noguchi K, Kowalski K, Traub R, Solodkin A, Iadarola MJ, and Ruda MA (1991) Dynorphin expression and Fos-like immunoreactivity following inflammation induced hyperalgesia are colocalized in spinal cord neurons. Brain Res Mol Brain Res 10:227-33.
163. Weihe E, Millan MJ, Hollt V, Nohr D, and Herz A (1989) Induction of the gene encoding pro-dynorphin by experimentally induced arthritis enhances staining for dynorphin in the spinal cord of rats. Neuroscience 31:77-95.
164. Watkins LR, Milligan ED, and Maier SF (2001) Glial activation: a driving force for pathological pain. Trends Neurosci 24:450-5.
165. Khasabov SG, Hamamoto DT, Harding-Rose C, and Simone DA (2007) Tumor-evoked hyperalgesia and sensitization of nociceptive dorsal horn neurons in a murine model of cancer pain. Brain Res 1180:7-19.
166. Gao YJ, Cheng JK, Zeng Q, Xu ZZ, Decosterd I, Xu X, and Ji RR (2009) Selective inhibition of JNK with a peptide inhibitor attenuates pain hypersensitivity and tumor growth in a mouse skin cancer pain model. Exp Neurol 219:146-55.